NeuroMetrix Reports Substantial Expansion of International Intellectual Property Assets for Quell Wearable Pain Relief Techno...
09 5월 2017 - 12:04AM
Business Wire
NeuroMetrix, Inc. (Nasdaq: NURO) reported today that Notices of
Allowance has been issued for patents covering key technological
features of the Company’s Quell® Wearable Pain Relief Technology™
by the European Patent Office, the Japan Patent Office, and the
State Intellectual Property Office of the People's Republic of
China.
The allowed patent claims address an essential element in the
Company’s proprietary technology that automatically controls nerve
stimulation to optimize pain relief. In particular, the patent
covers a novel calibration procedure that customizes nerve
stimulation for each Quell user.
In addition, the allowed patent claims protect the unique
integrated Quell design that combines a neurostimulator, an
electrode array, and an accelerometer. This technology enables
automatic adjustment of nerve stimulation based on the user’s
position and movement, with applications such as optimizing therapy
during sleep. The Company expects the three patents to formally
issue by the third quarter of 2017.
“We are pleased to have received these important Notice of
Allowances for the Quell technology in the European Union, Japan
and China. These are the three key expansion markets for the Quell
business,” said Shai N. Gozani, M.D., Ph.D., President and CEO of
NeuroMetrix. "We are currently in discussions with strategic
partners about licensing or distributing Quell outside our core
North American market. These patent claim allowances may help
advance these discussions towards formal agreements.”
About QuellQuell is designed for millions of people
suffering from chronic pain. The advanced wearable device is
lightweight and can be worn during the day while active, and at
night while sleeping. It has been cleared by the FDA for treatment
of chronic pain without a prescription. In a recent study, 81% of
Quell users reported an improvement in their chronic pain. Quell
users can personalize and manage therapy discreetly via the Quell
Relief app. Quell also offers advanced health tracking relevant to
chronic pain sufferers including pain, sleep, activity, and gait.
Quell was the winner of the 2016 SXSW (South by Southwest)
Innovation Award for Best Wearable Technology. Quell is available
at select healthcare professionals and retailers. Visit
QuellRelief.com for more information.
About NeuroMetrixNeuroMetrix is a commercial stage,
innovation driven healthcare company combining bioelectrical and
digital medicine to address chronic health conditions including
chronic pain, sleep disorders, and diabetes. The company's lead
product is Quell, an over-the-counter wearable therapeutic device
for chronic pain. Quell is integrated into a digital health
platform that helps patients optimize their therapy and decrease
the impact of chronic pain on their quality of life. The company
also markets DPNCheck®, a rapid point-of-care test for diabetic
neuropathy, which is the most common long-term complication of Type
2 diabetes. The company maintains an active research effort and has
several pipeline programs. The company is located in Waltham,
Massachusetts and was founded as a spinoff from the Harvard-MIT
Division of Health Sciences and Technology in 1996. For more
information, please visit NeuroMetrix.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170508005868/en/
NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief
Financial Officerneurometrix.ir@neurometrix.com
NeuroMetrix (NASDAQ:NUROW)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
NeuroMetrix (NASDAQ:NUROW)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
